What exactly changed in the MDT analyst rating on March 10, 2026?

On March 10, 2026, Leerink Partners reiterated **Outperform** and Needham reiterated **Buy** for Medtronic plc (MDT). Both firms maintained their ratings without publishing new price targets, citing acquisitions and M&A discipline as supporting factors.

Did either firm raise or lower MDT price targets with the maintained ratings?

No. The March 10, 2026 StreetInsider notes show both firms maintained ratings but did not announce new MDT price targets. The commentary emphasized acquisitions and execution rather than revised numbers.

How should I interpret the maintained MDT analyst rating for my portfolio?

A maintained MDT analyst rating indicates analysts still favor the stock but saw no need to change recommendation. For portfolios, treat these notes as confirmation of existing positive views and monitor earnings, acquisition integration, and device sales for future reassessments.

Analyst Ratings

Leerink, Needham Maintain Outperform and Buy on Medtronic plc (MDT) Mar 2026

ByHuzaifa Zahoor March 11, 2026March 11, 2026

On March 10, 2026, Leerink maintained an Outperform and Needham maintained a Buy on Medtronic plc (MDT). Our review of the MDT analyst rating shows both firms kept their positive stances while citing the company’s recent small tuck-in moves and an acquisition described as an “incremental positive.” These reiterations came during early U.S. trading on March 10, 2026 and coincided with modest intraday checks showing a -0.34% and -0.44% move for MDT in the cited notes. We examine the analyst reasoning, market response, and what the maintained ratings mean for investors.